Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.47 |
| ▸ | EDNRB | P24530 | 10/20 | 0.44 |
| ▸ | EDNRA | P25101 | 10/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354447 | 1.00 | KMT2A (0.47) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL27805427 | 0.91 | EDNRB (0.44) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL4434013 | 0.90 | KMT2A (0.42) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL27805325 | 0.87 | CTSG (0.42) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL27783661 | 0.87 | EDNRB (0.50) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL570417 | 0.85 | EDNRB (0.50) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL570658 | 0.85 | EDNRB (0.50) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL1067633 | 0.85 | EDNRB (0.50) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL15991494 | 0.85 | EDNRB (0.46) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL28101975 | 0.85 | EDNRB (0.46) | KMT2AEDNRBEDNRANR1I2KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104515816-B | The detection method of a kind of ambrisentan raw material and preparation related substance | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2016-04-20 | — | — | CN | claimed |
| CN-104515816-A | Detection method of substances relative to raw material and preparation of ambrisentan | TIANJIN INST PHARM RESEARCH | 2015-04-15 | — | — | CN | claimed |
| US-8404840-B2 | Process for the preparation of endothelin receptor antagonists | MSN LABORATORIES LIMITED (IL) | 2013-03-26 | — | — | US | claimed |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | MSN LABORATORIES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2350024-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN Laboratories Limited (IN) | 2011-08-03 | — | — | EP | claimed |
| WO-2010070658-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN LABORATORIES LIMITED (IN) | 2010-06-24 | — | — | WO | claimed |
| CN-104592129-B | A kind of improved method for preparing ambrisentan | 武汉启瑞药业有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-104693027-B | A kind of method synthesizing 2-hydroxyl-3-alkoxyl propionic ester compounds | 天津药物研究院 | 2016-06-22 | — | — | CN | disclosed |
| CN-104515816-B | The detection method of a kind of ambrisentan raw material and preparation related substance | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2016-04-20 | — | — | CN | disclosed |
| CN-104693027-A | Method for synthesizing 2-hydroxy-3-alkoxy propionate compounds | TIANJIN INST PHARM RESEARCH | 2015-06-10 | — | — | CN | disclosed |
| CN-104592129-A | Improved method used for preparing ambrisentan | QR PHARMACEUTICALS LTD | 2015-05-06 | — | — | CN | disclosed |
| CN-103012280-B | Method for preparing ambrisentan | JIANGSU KANION PHARMACEUTICAL | 2015-04-29 | — | — | CN | disclosed |
| CN-104515816-A | Detection method of substances relative to raw material and preparation of ambrisentan | TIANJIN INST PHARM RESEARCH | 2015-04-15 | — | — | CN | disclosed |
| US-5969134-A | CARDIOVASCULAR DISORDERS, VASOCONSTRICTION, HYPOTENSIVE AGENTS AND RELEASE OF ENDOTHELINS | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-19 | — | — | US | disclosed |
| US-5932730-A | Carboxylic acid derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-03 | — | — | US | disclosed |
| EP-0892788-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PRODUCTION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-27 | — | — | EP | disclosed |
| WO-1998041206-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE IN TREATING CANCER | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
| WO-1997038982-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PRODUCTION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-23 | — | — | WO | disclosed |
| EP-0785926-A1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011914-A1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | EDNRA, EDNRB, ECE1 | KMT2A 3733/4885KCNN4 844/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.